Who hip cartilage repair applies to in 2025

Focal cartilage damage in the hip joint — a discrete lesion on the acetabulum or femoral head — occupies a specific clinical space between early hip pain management and total hip replacement. The patients who typically fall within this space are younger adults: a German registry analysis of 116,179 hip cartilage procedures performed between 2006 and 2022 found regenerative techniques were applied at a mean patient age of 27.73 years. An intervention carried out at 28 must perform well not just at 2 or 5 years, but across the patient's working life — making outcome durability the principal clinical question.

Four techniques now carry 2025–2026 clinical data specific to the hip: AMIC (autologous matrix-induced chondrogenesis), OATS (osteochondral autograft transfer), osteochondral allograft transplantation (OCA), and ChondroFiller injection — an acellular injectable collagen scaffold delivered as an outpatient, ultrasound-guided procedure. Each suits a different defect size and clinical profile, and none applies meaningfully to end-stage or diffuse osteoarthritis, where hip replacement remains the appropriate pathway.

Selection extends beyond defect dimensions alone. A 2025 laboratory study confirmed that labrum and capsule integrity independently determines repair quality — cartilage restoration into a mechanically unstable hip joint produces measurably inferior outcomes. The whole joint environment, not only the chondral lesion, requires assessment before any restorative procedure is planned.

Microfracture, once the default first-line option for small defects, is the historical baseline all four techniques are measured against. Fibrocartilage breakdown at two to three years and cumulative damage to the subchondral bone plate have moved it outside modern first-line practice — its limitations are precisely what the newer techniques set out to address.

AMIC: what the 2025 meta-analysis found

Among the four techniques with current hip-specific data, AMIC carries the most consolidated 2025 evidence base. A systematic review and meta-analysis published that year drew on 12 papers covering 628 hips, returning a pooled success rate of 99.6% (95% CI 99.0–100.0%) and a mean improvement in modified Harris Hip Score of 35.8 points — a gain representing the difference between significant functional restriction and near-normal hip activity for most patients.

The most practically significant finding is not the headline success rate but the THA conversion data. Across four studies covering 209 hips, AMIC cohorts reported zero conversions to total hip arthroplasty at mid-term follow-up. Matched microfracture-alone comparator groups in the same studies converted at rates between 2% and 32.6%. For a patient in their mid-thirties, avoiding hip replacement at this stage is not a secondary consideration — it is the central goal of treatment.

Mechanically, AMIC augments the body's marrow response rather than harvesting or culturing cells. Microfracture perforations in the acetabular subchondral bone release marrow progenitor cells; a bilayer collagen I/III membrane is then secured over the defect to stabilise the blood clot and provide a scaffold for tissue formation. The procedure is completed in a single operative stage and is most applicable to focal acetabular defects of roughly 2–4 cm² arising from femoroacetabular impingement syndrome (FAIS).

Five-year structural data from published series report MOCART scores of approximately 67–69 for acetabular defects, with no revision surgery in arthroscopic cohorts — radiological evidence that the repair tissue holds at mid-term.

The UK NHS REPAIR pilot trial is currently running a prospective head-to-head comparison of AMIC against microfracture. The gap the trial is designed to close is one the existing meta-analysis cannot fill: its constituent studies are predominantly retrospective case series, not randomised controlled trials, and none draws on a British NHS population. Whether the functional and conversion-rate advantage holds under randomised conditions in UK practice remains the open question; the REPAIR results will address it directly.

OATS and OCA: autograft versus allograft for hip defects

The two osteochondral transfer options differ from AMIC in a fundamental way: they physically replace the damaged cartilage and underlying bone with a plug of intact osteochondral tissue rather than stimulating repair in situ. Defect size is what separates the two techniques from each other.

OATS draws donor tissue from the patient's own hip joint and is best suited to small femoral-head defects under 2 cm². A 2025 multicenter comparison reported a mean follow-up of 9.5 years in the autograft group, with mHHS around 87 and 0% conversion to total hip arthroplasty. Donor-site morbidity at the harvest zone is a genuine consideration and forms part of the pre-operative discussion, though it does not preclude OATS as a durable long-term option for appropriately selected patients.

OCA uses preserved cadaveric donor tissue, removing the harvest constraint and making it viable for considerably larger lesions. The leading 2025 series treated 24 patients at a mean age of 22.4 years, with a mean lesion size of 488 mm² — defects typically arising from developmental dysplasia, post-traumatic injury, Legg-Calvé-Perthes disease, or avascular necrosis. All cases required open surgical hip dislocation. Functional gains were real: mHHS improved from 62.1 to 83.9 and iHOT-12 from 35.5 to 77.5 at a mean of 47.9 months. However, 25% of patients — 6 of 24 — required conversion to hip arthroplasty at a mean of 3.8 years. That figure should be stated plainly to any patient weighing up this route.

One modifiable variable is graft preservation methodology. In a 33-patient cohort followed to a mean of 44.8 months, Missouri Osteochondral Preservation System (MOPS)-preserved grafts achieved 100% success versus 50% for standard preservation — a 47-fold difference in odds of success (p=0.001). This is a process-level factor within the surgical team's control rather than an intrinsic limitation of the technique.

Where defect size permits autograft harvest, OATS currently offers the more durable long-term record. Where the lesion is too large or the underlying pathology too complex, OCA remains the principal option despite its higher conversion risk. It is worth noting that the available evidence for both techniques in the hip consists predominantly of case series and retrospective cohorts; head-to-head randomised data do not yet exist.

ChondroFiller injection: the outpatient scaffold pathway

Unlike the three procedures described above, the ChondroFiller injection does not take place in an operating theatre. It is delivered as an ultrasound-guided outpatient injection under local anaesthesia or mild sedation — a meaningful distinction for patients who are earlier in the degeneration curve or who are not yet candidates for arthroscopic or open hip surgery.

The device itself is a CE-marked Class III acellular scaffold: a purified Type I collagen hydrogel that gels in situ after injection into the defect. No cells are harvested, cultured, or transferred. Instead, the scaffold creates a structural matrix that recruits the patient's own progenitor cells from the surrounding tissue — a process known as matrix-induced chondrogenesis. The repair work is done by the body; the injection provides the physical environment for it to happen.

2025 clinical evaluation data report statistically significant improvements in both IKDC and mHHS scores at 3, 6, and 12 months (p<0.05), and cellular tracking studies confirm that progenitor cell recruitment into the scaffold matrix does occur in practice. Follow-up horizons are shorter than those available for AMIC or OATS, so these findings should be read as promising early evidence rather than long-term proof of durability.

One point worth stating directly: the tissue that forms within the scaffold is predominantly fibrocartilage, not hyaline cartilage. Fibrocartilage is structurally less resilient than the native tissue it replaces — the same limitation that applies to microfracture — and patients should understand this before committing to any scaffold-based approach.

In terms of candidacy, the ChondroFiller injection is applicable to focal Grade III/IV defects, with standard criteria supporting lesions up to approximately 3 cm² and extended use up to 6 cm². Because it does not require the strict Tönnis Grade 0–1 joint status or isolated-defect criteria applied in arthroscopic surgical series, the outpatient injection route may be accessible to a somewhat broader range of patients.

What shapes outcomes across all four techniques

Three findings from the 2025 evidence base apply across all four techniques — regardless of which procedure a surgeon recommends.

Joint stability is the most actionable. A 2025 rabbit study found that preserving the labrum and capsule during microfracture produced significantly better cartilage healing — higher ICRS scores, superior defect filling, and greater type II collagen and aggrecan expression — compared with microfracture performed without stability preservation. Repair quality depends not only on what is placed in the defect but on the mechanical environment surrounding it. Surgeons who protect hip stability during or after any marrow stimulation or scaffold procedure are working with the biology rather than against it.

Biological environment shapes durability. A 4-year prospective study of 112 patients found MSC augmentation of microfracture produced sustained mHHS improvement from 63.5 to 87.2, against 66.2 to 83.0 for microfracture alone — and, critically, 20% of the control group showed late deterioration that was largely absent in the MSC group. This matters for any scaffold-based approach that relies on marrow stimulation: the conditions into which repair is asked to occur are a modifiable variable, not simply background.

Post-operative assessment is now standardised. The MERCH score (2023) provides a 7-domain MRI framework ranging from –20 to +60, requiring 3.0 Tesla imaging acquired at least 12 months after surgery. When applied in published AMIC cohorts, it has helped confirm that structural repair is occurring alongside functional improvement — for instance, MOCART-equivalent scores around 67–69 for acetabular defects — providing objective evidence that symptom scores alone cannot supply.

One limitation runs through the whole field: no long-term randomised trial has yet compared AMIC, OCA, and ChondroFiller injection head-to-head in the hip. Existing data are predominantly case series and retrospective cohorts — the signals are consistent and clinically meaningful, but patient selection and surgeon experience remain critical variables that future comparative trials may clarify.

Getting a hip cartilage repair assessment in Lincolnshire

The evidence across all four techniques points toward the same practical conclusion: correct patient selection determines outcome more than the procedure itself. AMIC suits 2–4 cm² acetabular defects in a joint with Tönnis Grade 0–1 status; the ChondroFiller injection addresses focal Grade III/IV lesions for patients not yet at the surgical threshold; OATS and OCA serve femoral-head defects graded by size and availability of donor tissue. Tönnis Grade ≥2 diffuse arthritis sits outside the scope of cartilage repair — a finding that redirects the pathway towards preservation or replacement discussion rather than scaffold surgery.

A hip cartilage assessment will typically involve clinical history, imaging review (3.0 Tesla MRI is preferred for structural characterisation and post-operative comparison), and a frank discussion of which technique — if any — matches the patient's defect size, joint status, age, and activity goals. Distinguishing a focal restorable lesion from diffuse articular degeneration is the most important clinical task before any procedure is considered.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics in Sleaford and Grantham serving Lincolnshire and the wider East Midlands catchment. No GP referral is required to book an initial consultation.

1. [1] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany: An Epidemiological Analysis from 2006 to 2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
2. [2] Osteochondral Allograft Transplantation of the Femoral Head via Surgical Hip Dislocation: Survivorship and PROMs at Minimum 2-Year Follow-Up. (2025). https://doi.org/10.1177/23259671251385115 https://doi.org/10.1177/23259671251385115
3. [3] Osteochondral Allograft and Autograft Transplant for Femoral Head Defects: A Multicenter Study. (2025). https://doi.org/10.1177/03635465251338062 https://doi.org/10.1177/03635465251338062
4. [4] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
5. [5] Autologous Matrix-Induced Chondrogenesis for the Treatment of Hip Acetabular Chondral Lesions Demonstrates Improved Outcomes: A Systematic Review. (2024). https://doi.org/10.1016/j.arthro.2024.04.028 https://doi.org/10.1016/j.arthro.2024.04.028
6. [6] Outcomes of Arthroscopic Joint Preservation Techniques for Chondral Lesions of the Hip: An Updated Systematic Review. (2023). https://doi.org/10.1016/j.arthro.2023.11.019 https://doi.org/10.1016/j.arthro.2023.11.019
7. [7] MID-TERM RESULTS OF AUTOLOGOUS MATRIX-INDUCED CHONDROGENESIS (AMIC) USED FOR LARGE CHONDRAL DEFECTS IN FEMOROACETABULAR IMPINGEMENT HIPS. (2023). https://doi.org/10.1302/1358-992x.2023.12.029 https://doi.org/10.1302/1358-992x.2023.12.029
8. [8] Preserving Hip Stability Yields Better Cartilage Repair With Microfracture Treatment: A Rabbit Study. (2025). https://doi.org/10.1016/j.asmr.2025.101284 https://doi.org/10.1016/j.asmr.2025.101284
9. [9] FP3.7 Hip articular cartilage repair with autologous mesenchymal stem cells (MSCs): 4-year results in prospective controlled study. (2025). https://doi.org/10.1093/jhps/hnaf011.025 https://doi.org/10.1093/jhps/hnaf011.025
10. [10] Defining hip cartilage repair: a modified Delphi study to establish the MERCH score. (2023). https://doi.org/10.1186/s40634-023-00676-y https://doi.org/10.1186/s40634-023-00676-y
11. [11] Outcomes associated with hip preservation using osteochondral allograft transplants and acetabular labrum reconstruction. (2024). https://doi.org/10.1177/11207000241288445 https://doi.org/10.1177/11207000241288445